Gilead Sciences (GILD) Cost of Revenue (2009 - 2026)

Gilead Sciences (GILD) has reported Cost of Revenue for 18 consecutive years, with $1.6 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cost of Revenue rose 5.2% year-over-year to $1.6 billion; the trailing twelve-month figure through Jun 2026 stood at $6.2 billion (changed 0.34% YoY), and the FY2025 full-year result was $6.2 billion, changed 0.27% from the prior year.
• Cost of Revenue advanced to $1.6 billion in Q2 2026 per GILD's latest filing, from $1.4 billion in the prior quarter.
• Across five years, Cost of Revenue topped out at $2.1 billion in Q4 2023 and bottomed at $1.4 billion in Q3 2022.
• Historically, Cost of Revenue has averaged $1.5 billion across 5 years, with a median of $1.5 billion in 2024.
• The sharpest annual moves came in 2022 and 2023: Cost of Revenue sank 46.86% in 2022, then surged 49.71% in 2023.
• Over 5 years, Cost of Revenue stood at $1.4 billion in 2022, then soared by 49.71% to $2.1 billion in 2023, then slipped by 24.35% to $1.6 billion in 2024, then increased by 2.72% to $1.6 billion in 2025, then slipped by 2.77% to $1.6 billion in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $1.6 billion, $1.4 billion, and $1.6 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.